Primary IOL implantation relatively safe for infant aphakia

Article

It is relatively safe and effective for infants to undergo primary IOL implantation for the correction of aphakia after having one cataract removed, according to new research out of China.

It is relatively safe and effective for infants to undergo primary IOL implantation for the correction of aphakia after having one cataract removed, according to new research out of China. Press-on spherical lenses are options for those unsuited to IOLs implantation add the investigators in an article appearing in Acta Ophthalmologica.

The study authors performed unilateral cataract extraction on 60 infants and then randomly assigned some of them to undergo IOL implantation and have any residual refractive error corrected with eyeglasses. Those patients not receiving IOLs were treated with press-on spherical lenses. The investigators measured grated visual acuity (VA) and followed the patients for up to a year.

All infants experienced better LogMAR VA in their operated eyes at 1 year compared with 1 month after surgery, although those receiving IOLs saw greater improvement. Those undergoing lens implantation also were more likely to experience serious inflammation, however, as well as visual axis opacity.

The prevalence of glaucoma was the same in both groups. There were no other complications.

To read an abstract of the study, visit the journal's website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.